BB Biotech AG, through its subsidiary Biotech Growth N.V., has sold a significant portion of its holdings in ESSA Pharma Inc . (NASDAQ:EPIX). The transactions, which occurred on November 1, involved the sale of 7,879,583 common shares. The sales were conducted at prices ranging from $1.513 to $1.532 per share, resulting in total proceeds of approximately $12,018,409.
Following these transactions, BB Biotech AG no longer holds any shares in ESSA Pharma. This move marks a complete divestment from the company by the Swiss investment firm, which was previously a ten percent owner through its subsidiary.
In other recent news, ESSA Pharma has experienced several significant developments. The company announced the termination of its drug candidate masofaniten's development after a Phase 2 study indicated the drug did not meet the targeted efficacy profile. Following this, Oppenheimer downgraded ESSA Pharma shares from Outperform to Perform, and Piper Sandler also downgraded the company's stock from Overweight to Neutral. Jones Trading followed suit, downgrading ESSA Pharma's shares from "Buy" to "Hold" due to the unfavorable trial data.
Despite these setbacks, ESSA Pharma is initiating a strategic process to explore various options aimed at maximizing shareholder value. The company's last reported cash balance of $126.8 million is expected to provide sufficient flexibility to assess potential opportunities. The ongoing Phase 2 dose expansion is actively enrolling patients across multiple sites in the US, Canada, and Australia, with further participation from Europe anticipated.
Piper Sandler has reaffirmed its Overweight rating for ESSA Pharma, following the presentation of updated trial data showing improved efficacy. Meanwhile, an Ipsen (EPA:IPN) employee, Dishant Gupta, is set to plead guilty to securities fraud for insider trading based on confidential information regarding the company's acquisition plans. These are among the recent developments shaping ESSA Pharma's current business landscape.
InvestingPro Insights
The recent divestment by BB Biotech AG from ESSA Pharma Inc. (NASDAQ:EPIX) aligns with several key financial indicators and market trends highlighted by InvestingPro. EPIX's stock has experienced significant volatility and downward pressure, with InvestingPro data showing a staggering 73.01% decline in the past month and a 72.83% drop over the last year. This steep decline is further emphasized by the stock trading at just 14.48% of its 52-week high.
InvestingPro Tips suggest that EPIX's stock is currently in oversold territory, based on its Relative Strength Index (RSI). This could indicate that the recent sell-off, including BB Biotech's divestment, may have pushed the stock to potentially undervalued levels. However, it's crucial to note that EPIX is not profitable over the last twelve months, and analysts do not anticipate profitability this year, which may have influenced BB Biotech's decision to exit its position.
Despite these challenges, EPIX maintains a stronger cash position than debt on its balance sheet, with liquid assets exceeding short-term obligations. This financial flexibility could be crucial as the company navigates its current unprofitable status.
For investors seeking a more comprehensive analysis, InvestingPro offers 14 additional tips for EPIX, providing a deeper understanding of the company's financial health and market position. These insights could be particularly valuable in light of the recent major shareholder exit and the stock's volatile performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.